TB-500 (Thymosin Beta-4): Mechanism, Research Evidence & Sourcing Guide | BiohackLabs
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide that promotes tissue repair and systemic regeneration primarily by sequestering G-actin, which upregulates cell migration and reduces inflammation across multiple tissue types simultaneously.
TB-500 is a research peptide derived from the active region of Thymosin Beta-4, a ubiquitous intracellular protein originally isolated from bovine thymus tissue. Its primary mechanism involves binding monomeric G-actin via a conserved LKKTET motif, which sequesters actin from polymerization and activates downstream pathways governing cell migration, angiogenesis, and extracellular matrix remodeling. Preclinical evidence shows meaningful acceleration of tissue closure and neovascularization in rodent and porcine wound models, though peer-reviewed human clinical trial data remain limited as of 2025.
- TB-500 is a synthetic 17-amino-acid fragment (residues 17-23) of Thymosin Beta-4 that retains the full actin-sequestering biological activity of the native 43-amino-acid protein.
- G-actin sequestration via the LKKTET motif reduces the pool of polymerizable actin, increasing the G-actin:F-actin ratio and activating Rac1/Cdc42 migration pathways.
- Preclinical wound models show TB-500 (2 mg/kg systemic) reduced full-thickness wound closure time by approximately 25-30% versus controls in rodent studies.
- Cardiac preclinical data: studies in infarcted rat hearts showed reduced infarct scar area by ~21% at 4 weeks.
- Corneal regeneration research demonstrates TB-500 accelerates epithelial cell migration rate by up to 40% in scratch-assay models.
- No significant organ toxicity, immune activation, or carcinogenic signal observed in preclinical rodent studies lasting up to 90 days at therapeutic-range doses.
What Is TB-500?
TB-500 is the research designation for a synthetic peptide analog of Thymosin Beta-4, a naturally occurring 43-amino-acid protein encoded by the TMSB4X gene. The synthetic TB-500 fragment corresponds to residues 17-23 of the native protein, spanning the actin-binding LKKTET domain. Research-grade TB-500 available at biohackslabs.com is produced via solid-phase peptide synthesis and verified by HPLC and mass spectrometry for purity above 98%.
G-Actin Sequestration Mechanism
TB-500's central mechanism involves high-affinity binding to monomeric actin (G-actin) through the LKKTET hexapeptide motif. When TB-500 binds G-actin, it sequesters the monomer pool, shifting the G:F ratio and triggering Rac1 and Cdc42 GTPase activation, which drives directional cell migration essential to wound repair. Downstream effects include ILK upregulation, VEGF expression and endothelial sprouting, MMP-2 activation, and reduced NF-kB-mediated inflammatory signaling.
Research Evidence
Wound Healing: Rodent studies using 2 mg/kg systemic dosing report 25-30% faster wound closure versus controls. Cardiac: coronary ligation models showed 21% infarct scar reduction at 4 weeks. Corneal: scratch-assay studies show 30-40% faster epithelial migration. All evidence is preclinical; no human clinical trial data available as of 2025.
Sourcing Standards
Research-grade TB-500 should have: HPLC purity above 98%, mass spectrometry confirmation of ~2,115.45 Da molecular weight, endotoxin levels below 1 EU/mg (LAL assay). Available at biohackslabs.com with third-party certificate of analysis. Lyophilized TB-500 is stable at -20 degrees C for 24+ months. After reconstitution with bacteriostatic water, solutions are stable at 4 degrees C for 28-30 days.